~~<i id='AD19EE256A'><strike id='AD19EE256A'><tt id='AD19EE256A'><pre id='AD19EE256A'></pre></tt></strike></i>~~

Home» focus» explore

explore

author：leisure time 2025-09-29 09:01:08 Page View：465

HHS 2020 — PhRMA is suing the Biden administration over its new Medicare drug price negotiation program. Graeme Sloan/Sipa USA

WASHINGTON — After losing the drug pricing fight on Capitol Hill, PhRMA is taking its battle to the courts.

The pharmaceutical industry’s biggest lobbying group on Wednesday filed a long-expected lawsuit challenging Democrats’ drug pricing law that allowed Medicare to start negotiating prices for certain medicines.

PhRMA joins a growing club of companies and trades challenging the law. Merck, Bristol Myers Squibb, and the Chamber of Commerce have already filed similar suits in different courts.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug
Next article： Walensky prepares to leave CDC — and Congress — behind

Wikipedia

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

"Arrestingcancer."ADAMFEUERSTEIN/STATYou’rereadingthewebeditionofASCOin30Seconds,STAT’sguidetotheAme

ChatGPT in medicine: STAT answers readers' burning questions

MikeReddyforSTATArtificialintelligenceisoftendescribedasablackbox:anunknowable,mysteriousforcethatop

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

WhichpresentationsareworthcatchingatASCOthisweekend?Whatisexon-skipping?Andhowdoyoupronouncebronchie